We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
- Authors
Vermij, Lisa; Jobsen, Jan J.; León-Castillo, Alicia; Brinkhuis, Mariel; Roothaan, Suzan; Powell, Melanie E.; de Boer, Stephanie M.; Khaw, Pearly; Mileshkin, Linda R.; Fyles, Anthony; Leary, Alexandra; Genestie, Catherine; Jürgenliemk-Schulz, Ina M.; Crosbie, Emma J.; Mackay, Helen J.; Nijman, Hans. W.; Nout, Remi A.; Smit, Vincent T. H. B. M.; Creutzberg, Carien L.; Horeweg, Nanda
- Abstract
Background: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. Methods: Paraffin-embedded tumour samples of women with high-risk EC (HR-EC) from the PORTEC-3 trial (n = 424), and a Dutch prospective clinical cohort called MST (n = 256), were used. All cases were molecularly classified. Expression of L1CAM, ER and PR were analysed by whole-slide immunohistochemistry and CTNNB1 mutations were assessed with a next-generation sequencing. Kaplan–Meier method, log-rank tests and Cox's proportional hazard models were used for survival analysis. Results: In total, 648 HR-EC were included. No independent prognostic value of ER, PR, L1CAM, and CTNNB1 was found, while age, stage, and adjuvant chemotherapy had an independent impact on risk of recurrence. Subgroup-analysis showed that only in NSMP HR-EC, ER-positivity was independently associated with a reduced risk of recurrence (HR 0.33, 95%CI 0.15–0.75). Conclusions: We confirmed the prognostic impact of the molecular classification, age, stage, and adjuvant CTRT in a large cohort of high-risk EC. ER-positivity is a strong favourable prognostic factor in NSMP HR-EC and identifies a homogeneous subgroup of NSMP tumours. Assessment of ER status in high-risk NSMP EC is feasible in clinical practice and could improve risk stratification and treatment.
- Publication
British Journal of Cancer, 2023, Vol 128, Issue 7, p1360
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-023-02141-0